Get the Stockscreener App
120.07
1.20%
-1.46
After Hours:
120.07
Jazz Pharmaceuticals Plc stock is traded at $120.07, with a volume of 462.52K.
It is down -1.20% in the last 24 hours and down -1.44% over the past month.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
See More
Previous Close:
$121.53
Open:
$121.97
24h Volume:
462.52K
Relative Volume:
0.80
Market Cap:
$7.26B
Revenue:
$3.99B
Net Income/Loss:
$463.16M
P/E Ratio:
16.91
EPS:
7.1
Net Cash Flow:
$1.10B
1W Performance:
-3.98%
1M Performance:
-1.44%
6M Performance:
+7.81%
1Y Performance:
-3.72%
1-Day Range:
$119.44
$122.04
1-Week Range:
$119.44
$127.14
52-Week Range:
$99.06
$134.17
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Name
Jazz Pharmaceuticals Plc
Sector
Industry
Phone
353-1-634-7800
Address
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
120.07 | 7.26B | 3.99B | 463.16M | 1.10B | 7.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-05-24 | Initiated | Goldman | Buy |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Nov-27-23 | Downgrade | UBS | Buy → Neutral |
| Sep-29-23 | Initiated | Raymond James | Mkt Perform |
| Jun-12-23 | Resumed | Wells Fargo | Equal Weight |
| Dec-09-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-06-22 | Downgrade | Goldman | Buy → Neutral |
| Nov-19-21 | Resumed | Goldman | Buy |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Oct-05-21 | Initiated | Citigroup | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| May-19-21 | Resumed | JP Morgan | Overweight |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-03-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-29-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-09-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-14-20 | Downgrade | Goldman | Neutral → Sell |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-06-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-28-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jul-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-06-20 | Initiated | Jefferies | Buy |
| Mar-12-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Neutral |
| Aug-21-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-18 | Reiterated | B. Riley FBR | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jul-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-23-18 | Reiterated | H.C. Wainwright | Neutral |
| Mar-19-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Jazz Pharmaceuticals Plc Stock (JAZZ) Latest News
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Bruce C. Cozadd Sells 1,500 Shares - MarketBeat
Jazz Pharmaceuticals Joins the Movement for Awareness and Support on World Cancer Day with The Upside Down Challenge - StreetInsider.com
Meritage Portfolio Management Reduces Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Sees Large Decrease in Short Interest - MarketBeat
Institute for Wealth Management LLC. Makes New $260,000 Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Insider Sell: Bruce Cozadd Sells Shares of Jazz Pharmaceuticals PLC - GuruFocus.com
Jazz Pharmaceuticals CEO Bruce Cozadd sells shares worth $183,465 - MSN
Why Jazz (JAZZ) is Poised to Beat Earnings Estimates Again - Yahoo Finance
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Acquired by BTC Capital Management Inc. - MarketBeat
Robeco Institutional Asset Management B.V. Raises Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Leerink Partnrs Has Strong Forecast for JAZZ FY2024 Earnings - MarketBeat
KBC Group NV Increases Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Jazz Pharmaceuticals Plc to Host Earnings Call - ACCESS Newswire
Jazz Pharmaceuticals (NASDAQ:JAZZ) investors are sitting on a loss of 14% if they invested five years ago - Simply Wall St
Narcolepsy Market Future Business Opportunities 2025-2032 | - openPR
Pacer Advisors Inc. Purchases 115,102 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Perpetual Ltd Sells 81,043 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Lmcg Investments LLC Takes $5.60 Million Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
MassMutual Private Wealth & Trust FSB Has $2.19 Million Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
2,442 Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Acquired by Aaron Wealth Advisors LLC - MarketBeat
Arkadios Wealth Advisors Invests $716,000 in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Short Interest Update - MarketBeat
Kera Capital Partners Inc. Buys New Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Wedge Capital Management L L P NC Sells 48,679 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Empirical Asset Management LLC Invests $5.36 Million in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Hennion & Walsh Asset Management Inc. Has $4.42 Million Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Burney Co. Grows Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
JP Morgan 2025: Jazz Pharmaceuticals focusing on oncology pipeline - MSN
14 Best 52-Week High Stocks To Buy According to Analysts - Insider Monkey
JAZZ (Jazz Pharmaceuticals) Growth Rank : 7 (As of Jan. 15, 2025) - GuruFocus.com
Jazz Pharmaceuticals plc (JAZZ): Analysts Recommend This 52-Week High Stocks Now - Insider Monkey
Serina Therapeutics Appoints Former Jazz Pharmaceuticals Finance Executive Karen Wilson to Board - StockTitan
Acute Lymphocytic Leukemia Pipeline Analysis 2024: FDA - openPR
With EPS Growth And More, Jazz Pharmaceuticals (NASDAQ:JAZZ) Makes An Interesting Case - Simply Wall St
Jazz Pharmaceuticals CEO sells shares worth $185,145 By Investing.com - Investing.com Nigeria
Insider Selling: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Sells 1,500 Shares of Stock - MarketBeat
Jazz Pharmaceuticals CEO sells shares worth $185,145 - Investing.com India
Centre Asset Management LLC Makes New Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals Plc Stock (JAZZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):